Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications

Bibliography

• GRANT BF, STINSON FS, HASIN DS et al.: Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry (2005) 66(10):1205-1215.
   PubMed Web of Science ®Google Scholar
• KESSLER RC, CHIU WT, DEMLER O, MERIKANGAS KR, WALTERS EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry (2005) 62(6):617-627.
   PubMed Web of Science ®Google Scholar
• EVANS DL, CHARNEY DS, LEWIS L et al.: Mood disorders in the medically ill: scientific review and recommendations. Biol. Psychiatry (2005) 58(3):175-189.
   PubMed Web of Science ®Google Scholar
• MICHAUD CM, MURRAY CJ, BLOOM BR: Burden of disease – implications for future research. JAMA (2001) 285(5):535-539.
   PubMed Web of Science ®Google Scholar
• CALABRESE JR, HIRSCHFELD RM, REED M et al.: Impact of bipolar disorder on a US community sample. J. Clin. Psychiatry (2003) 64(4):425-432.
   PubMed Web of Science ®Google Scholar
• WOODS SW: The economic burden of bipolar disease. J. Clin. Psychiatry (2000) 61(Suppl. 13):38-41.
   PubMed Web of Science ®Google Scholar
• CRADDOCK N, JONES I: Genetics of bipolar disorder. J. Med. Genet. (1999) 36(8):585-594.
   PubMed Web of Science ®Google Scholar
• SULLIVAN PF, NEALE MC, KENDLER KS: Genetic epidemiology of major depression: review and meta-analysis. Am. J. Psychiatry (2000) 157(10):1552-1562.
   PubMed Web of Science ®Google Scholar
• CARDNO AG, MARSHALL EJ, COID B et al.: Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch. Gen. Psychiatry (1999) 56(2):162-168.
   PubMed Web of Science ®Google Scholar
• POULSEN P, KYVIK KO, VAAG A, BECK-NIELSEN H: Heritability of Type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance-a population-based twin study. Diabetologia (1999) 42(2):139-145.
   PubMed Web of Science ®Google Scholar
• MANJI HK, MOORE GJ, RAJKOWSKA G, CHEN G: Neuroplasticity and cellular resilience in mood disorders. Mol. Psychiatry (2000) 5(6):578-593.
   PubMed Web of Science ®Google Scholar
• QUIROZ JA, SINGH J, GOULD TD et al.: Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Mol. Psychiatry (2004) 9(8):756-776.
   PubMed Web of Science ®Google Scholar
• HENINGER GR, CHARNEY DS, STERNBERG DE: Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression. Arch. Gen. Psychiatry (1983) 40(12):1335-1342.
   PubMed Web of Science ®Google Scholar
• BAUER M, FORSTHOFF A, BAETHGE C et al.: Lithium augmentation therapy in refractory depression-update 2002. Eur. Arch. Psychiatry Clin. Neurosci. (2003) 253(3):132-139.
   PubMed Web of Science ®Google Scholar
• SCHOU M: Lithium treatment at 52. J. Affect. Disord. (2001) 67(1-3):21-32.
   PubMed Web of Science ®Google Scholar
• CADE JFJ: Lithium salts in the treatment of psychotic excitement. Med. J. Aust. (1949) 2:349-352.
   PubMed Web of Science ®Google Scholar
• GAO K, GAJWANI P, ELHAJ O, CALABRESE JR: Typical and atypical antipsychotics in bipolar depression. J. Clin. Psychiatry (2005) 66(11):1376-1385.
   PubMed Web of Science ®Google Scholar
• WALSH BT, SEIDMAN SN, SYSKO R, GOULD M: Placebo response in studies of major depression: variable, substantial, and growing. JAMA (2002) 287(14):1840-1847.
   PubMed Web of Science ®Google Scholar
• GOULD TD, QUIROZ JA, SINGH J, ZARATE CA, MANJI HK: Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol. Psychiatry (2004) 9(8):734-755.
   PubMed Web of Science ®Google Scholar
• YORK JD, PONDER JW, MAJERUS PW: Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc. Natl. Acad. Sci. USA (1995) 92(11):5149-5153.
   PubMed Web of Science ®Google Scholar
• SPIEGELBERG BD, XIONG JP, SMITH JJ, GU RF, YORK JD: Cloning and characterization of a mammalian lithium-sensitive bisphosphate 3’-nucleotidase inhibited by inositol 1,4-bisphosphate. J. Biol. Chem. (1999) 274(19):13619-13628.
   PubMed Web of Science ®Google Scholar
• RAY WJ, JR., SZYMANKI ES, NG L: The binding of lithium and of anionic metabolites to phosphoglucomutase. Biochim. Biophys. Acta (1978) 522(2):434-442.
   PubMed Web of Science ®Google Scholar
• SRINIVASAN C, TOON J, AMARI L et al.: Competition between lithium and magnesium ions for the G-protein transducin in the guanosine 5’-diphosphate bound conformation. J. Inorg. Biochem. (2004) 98(5):691-701.
   PubMedGoogle Scholar
• AVISSAR S, SCHREIBER G, DANON A, BELMAKER RH: Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature (1988) 331(6155):440-442.
   PubMed Web of Science ®Google Scholar
• MINADEO N, LAYDEN B, AMARI LV et al.: Effect of Li+ upon the Mg2+-dependent activation of recombinant Gialpha1. Arch. Biochem. Biophys. (2001) 388(1):7-12.
   PubMedGoogle Scholar
• BERRIDGE MJ, DOWNES CP, HANLEY MR: Neural and developmental actions of lithium: a unifying hypothesis. Cell (1989) 59(3):411-419.
   PubMed Web of Science ®Google Scholar
• MAJERUS PW: Inositol phosphate biochemistry. Ann. Rev. Biochem. (1992) 61:225-250.
   PubMed Web of Science ®Google Scholar
• ALLISON JH, STEWART MA: Reduced brain inositol in lithium-treated rats. Nat. New Biol. (1971) 233(43):267-268.
   PubMedGoogle Scholar
• ATACK JR: Lithium, phosphatidylinositol signaling, and bipolar disorder. In: Bipolar Medications: Mechanism of Action, Manji HK et al. (Eds) American Psychiatric Press, Inc., Washington, DC (2000):1-30.
   Google Scholar
• MANJI HK, LENOX RH: Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol. Psychiatry (1999) 46(10):1328-1351.
   PubMed Web of Science ®Google Scholar
• WILLIAMS RS, CHENG L, MUDGE AW, HARWOOD AJ: A common mechanism of action for three mood-stabilizing drugs. Nature (2002) 417(6886):292-295.
   PubMed Web of Science ®Google Scholar
• ATACK JR, COOK SM, WATT AP, FLETCHER SR, RAGAN CI: In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. J. Neurochem. (1993) 60(2):652-658.
   PubMedGoogle Scholar
• ATACK JR, PRIOR AM, FLETCHER SR et al.: Effects of L-690,488, a prodrug of the bisphosphonate inositol monophosphatase inhibitor L-690,330, on phosphatidylinositol cycle markers. J. Pharmacol. Exp. Ther. (1994) 270(1):70-76.
   PubMed Web of Science ®Google Scholar
• KLEIN PS, MELTON DA: A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA (1996) 93(16):8455-8459.
   PubMed Web of Science ®Google Scholar
• STAMBOLIC V, RUEL L, WOODGETT JR: Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. (1996) 6(12):1664-1668.
   PubMed Web of Science ®Google Scholar
• BHAT RV, SHANLEY J, CORRELL MP et al.: Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. USA (2000) 97(20):11074-11079.
   PubMed Web of Science ®Google Scholar
• SAYAS CL, ARIAENS A, PONSIOEN B, MOOLENAAR WH: GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. Mol. Biol. Cell (2006) 17(4):1834-1844.
   PubMedGoogle Scholar
• FAN G, BALLOU LM, LIN RZ: Phospholipase C-independent activation of glycogen synthase kinase-3 β and C-terminal Src kinase by Gαq. J. Biol. Chem. (2003) 278(52):52432-52436.
   PubMedGoogle Scholar
• FRAME S, COHEN P: GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. (2001) 359(Pt 1):1-16.
   PubMed Web of Science ®Google Scholar
• ZHANG F, PHIEL CJ, SPECE L, GURVICH N, KLEIN PS: Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J. Biol. Chem. (2003) 278(35):33067-33077.
   PubMed Web of Science ®Google Scholar
• BENNECIB M, GONG CX, GRUNDKE-IQBAL I, IQBAL K: Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett. (2000) 485(1):87-93.
   PubMed Web of Science ®Google Scholar
• TANJI C, YAMAMOTO H, YORIOKA N et al.: A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3beta (GSK-3beta) and mediates protein kinase A-dependent inhibition of GSK-3beta. J. Biol. Chem. (2002) 277(40):36955-36961.
   PubMedGoogle Scholar
• FIOL CJ, MAHRENHOLZ AM, WANG Y, ROESKE RW, ROACH PJ: Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem. (1987) 262(29):14042-14048.
   PubMed Web of Science ®Google Scholar
• FRAME S, COHEN P, BIONDI RM: A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell (2001) 7(6):1321-1327.
   PubMed Web of Science ®Google Scholar
• DAJANI R, FRASER E, ROE SM et al.: Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell (2001) 105(6):721-732.
   PubMed Web of Science ®Google Scholar
• GRIMES CA, JOPE RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. (2001) 65(4):391-426.
   PubMed Web of Science ®Google Scholar
• ELDAR-FINKELMAN H, ILOUZ R: Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment. Expert Opin. Investig. Drugs (2003) 12(9):1511-1519.
   PubMed Web of Science ®Google Scholar
• BONDY CA, CHENG CM: Signaling by insulin-like growth factor 1 in brain. Eur. J. Pharmacol. (2004) 490(1-3):25-31.
   PubMed Web of Science ®Google Scholar
• BRYWE KG, MALLARD C, GUSTAVSSON M et al.: IGF-I neuroprotection in the immature brain after hypoxia-ischemia, involvement of Akt and GSK3beta? Eur. J. Neurosci. (2005) 21(6):1489-1502.
   PubMedGoogle Scholar
• WATCHARASIT P, BIJUR GN, ZMIJEWSKI JW et al.: Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc. Natl. Acad. Sci. USA (2002) 99(12):7951-7955.
   PubMed Web of Science ®Google Scholar
• LINSEMAN DA, BUTTS BD, PRECHT TA et al.: Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J. Neurosci. (2004) 24(44):9993-10002.
   PubMed Web of Science ®Google Scholar
• LOGAN CY, NUSSE R: The Wnt signaling pathway in development and disease. Ann. Rev. Cell Dev. Biol. (2004) 20:781-810.
   PubMed Web of Science ®Google Scholar
• HUANG HC, KLEIN PS: The Frizzled family: receptors for multiple signal transduction pathways. Genome Biol. (2004) 5(7):234.
   PubMed Web of Science ®Google Scholar
• RYVES WJ, HARWOOD AJ: Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun. (2001) 280(3):720-725.
   PubMed Web of Science ®Google Scholar
• GURVICH N, KLEIN PS: Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. (2002) 96:45-66.
   PubMed Web of Science ®Google Scholar
• MUNOZ-MONTANO JR, MORENO FJ, AVILA J, DIAZ-NIDO J: Lithium inhibits Alzheimer’s disease-like tau protein phosphorylation in neurons. FEBS Lett. (1997) 411(2-3):183-188.
   PubMed Web of Science ®Google Scholar
• DE SARNO P, LI X, JOPE RS: Regulation of Akt and glycogen synthase kinase-3beta phosphorylation by sodium valproate and lithium. Neuropharmacology (2002) 43(7):1158-1164.
   PubMed Web of Science ®Google Scholar
• ROH MS, EOM TY, ZMIJEWSKA AA et al.: Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine. Biol. Psychiatry (2005) 57:278-286.
   PubMed Web of Science ®Google Scholar
• PHIEL CJ, WILSON CA, LEE VM, KLEIN PS: GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature (2003) 423(6938):435-439.
   PubMed Web of Science ®Google Scholar
• DE FERRARI GV, CHACON MA, BARRIA MI et al.: Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol. Psychiatry (2003) 8(2):195-208.
   PubMed Web of Science ®Google Scholar
• PEREZ M, HERNANDEZ F, LIM F, DIAZ-NIDO J, AVILA J: Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis. (2003) 5(4):301-308.
   PubMed Web of Science ®Google Scholar
• GOULD TD, CHEN G, MANJI HK: In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology (2004) 29(1):32-38.
   PubMed Web of Science ®Google Scholar
• O’BRIEN WT, HARPER AD, JOVE F et al.: Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. (2004) 24(30):6791-6798.
   PubMed Web of Science ®Google Scholar
• SU Y, RYDER J, LI B et al.: Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry (2004) 43(22):6899-6908.
   PubMed Web of Science ®Google Scholar
• GOULD TD, PICCHINI AM, EINAT H, MANJI HK: Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr. Drug Targets (2006) In Press.
   PubMedGoogle Scholar
• CHALECKA-FRANASZEK E, CHUANG DM: Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. USA (1999) 96(15):8745-8750.
   PubMed Web of Science ®Google Scholar
• KOZLOVSKY N, AMAR S, BELMAKER RH, AGAM G: Psychotropic drugs affect Ser9-phosphorylated GSK-3beta protein levels in rodent frontal cortex. Int. J. Neuropsychopharmacol. (2005):1-6.
   Google Scholar
• KIRSHENBOIM N, PLOTKIN B, SHLOMO SB, KAIDANOVICH-BEILIN O, ELDAR-FINKELMAN H: Lithium-mediated phosphorylation of glycogen synthase kinase-3b involves PI3 kinase-dependent activation of protein kinase C-alpha. J. Mol. Neurosci. (2004) 24(2):237-246.
   PubMedGoogle Scholar
• EMRICH HM, VON ZERSSEN D, KISSLING W, MOLLER HJ, WINDORFER A: Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch. Psychiatr. Nervenkr. (1980) 229(1):1-16.
   PubMedGoogle Scholar
• LAMBERT PA, VENAUD G: [Use of valpromide in psychiatric therapeutics]. Encephale (1987) 13(6):367-373.
   PubMedGoogle Scholar
• BOWDEN CL, BRUGGER AM, SWANN AC et al.: Efficacy of divalproex versus lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA (1994) 271(12):918-924.
   PubMed Web of Science ®Google Scholar
• POPE HG, JR., MCELROY SL, KECK PE, JR., HUDSON JI: Valproate in the treatment of acute mania. A placebo-controlled study. Arch. Gen. Psychiatry (1991) 48(1):62-68.
   PubMed Web of Science ®Google Scholar
• CHEN G, HUANG LD, JIANG YM, MANJI HK: The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. (1999) 72(3):1327-1330.
   PubMed Web of Science ®Google Scholar
• GRIMES AC, JOPE RS: CREB DNA binding activity is inhibited by glycogen synthase kinase-3beta and facilitated by lithium. J. Neurochem. (2001) 78(6):1219-1232.
   PubMed Web of Science ®Google Scholar
• WERSTUCK GH, KIM AJ, BRENSTRUM T et al.: Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds. Bioorg. Med. Chem. Lett (2004) 14(22):5465-5467.
   PubMed Web of Science ®Google Scholar
• KIM AJ, SHI Y, AUSTIN RC, WERSTUCK GH: Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell Sci. (2005) 118(Pt 1):89-99.
   PubMed Web of Science ®Google Scholar
• PHIEL CJ, ZHANG F, HUANG EY et al.: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. (2001) 276(39):36734-36741.
   PubMed Web of Science ®Google Scholar
• HALL AC, BRENNAN A, GOOLD RG et al.: Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol. Cell. Neurosci. (2002) 20(2):257-270.
   PubMed Web of Science ®Google Scholar
• LI X, ZHU W, ROH MS et al.: In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology (2004) 29(8):1426-1431.
   PubMed Web of Science ®Google Scholar
• BLIER P, ABBOTT FV: Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J. Psychiatry Neurosci. (2001) 26(1):37-43.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE S, SACKEIM HA, SCHNUR DB: Electroconvulsive therapy of acute manic episodes: a review of 50 years’ experience. Am. J. Psychiatry (1994) 151(2):169-176.
   PubMed Web of Science ®Google Scholar
• ROH MS, KANG UG, SHIN SY et al.: Biphasic changes in the Ser-9 phosphorylation of glycogen synthase kinase-3beta after electroconvulsive shock in the rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry (2003) 27(1):1-5.
   PubMedGoogle Scholar
• KANG UG, ROH MS, JUNG JR et al.: Activation of protein kinase B (Akt) signaling after electroconvulsive shock in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry (2004) 28(1):41-44.
   PubMedGoogle Scholar
• MADSEN TM, NEWTON SS, EATON ME, RUSSELL DS, DUMAN RS: Chronic electroconvulsive seizure up-regulates beta-catenin expression in rat hippocampus: role in adult neurogenesis. Biol. Psychiatry (2003) 54(10):1006-1014.
   PubMed Web of Science ®Google Scholar
• MALBERG JE, EISCH AJ, NESTLER EJ, DUMAN RS: Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. (2000) 20(24):9104-9110.
   PubMed Web of Science ®Google Scholar
• KANG UG, SEO MS, ROH MS et al.: The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett. (2004) 560(1-3):115-119.
   PubMed Web of Science ®Google Scholar
• EMAMIAN ES, HALL D, BIRNBAUM MJ, KARAYIORGOU M, GOGOS JA: Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. (2004) 36(2):131-137.
   PubMed Web of Science ®Google Scholar
• ALIMOHAMAD H, RAJAKUMAR N, SEAH YH, RUSHLOW W: Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol. Psychiatry (2005) 57(5):533-542.
   PubMed Web of Science ®Google Scholar
• ALIMOHAMAD H, SUTTON L, MOUYAL J, RAJAKUMAR N, RUSHLOW WJ: The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats. J. Neurochem. (2005) 95(2):513-525.
   PubMedGoogle Scholar
• LI X, ROSBOROUGH KM, FRIEDMAN AB, ZHU W, ROTH KA: Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int. J. Neuropsychopharmacol. (2006):1-13.
   PubMedGoogle Scholar
• BASTA-KAIM A, BUDZISZEWSKA B, JAWORSKA-FEIL L et al.: Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology (2005) 31(4):853-865.
   Google Scholar
• PAYNE JL: The role of estrogen in mood disorders in women. Int. Rev. Psychiatry (2003) 15(3):280-290.
   PubMed Web of Science ®Google Scholar
• BLOCH M, DALY RC, RUBINOW DR: Endocrine factors in the etiology of postpartum depression. Compr. Psychiatry (2003) 44(3):234-246.
   PubMed Web of Science ®Google Scholar
• GRIGORIADIS S, KENNEDY SH: Role of estrogen in the treatment of depression. Am. J. Ther. (2002) 9(6):503-509.
   PubMedGoogle Scholar
• CARDONA-GOMEZ P, PEREZ M, AVILA J, GARCIA-SEGURA LM, WANDOSELL F: Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus. Mol. Cell. Neurosci. (2004) 25(3):363-373.
   PubMed Web of Science ®Google Scholar
• GOODENOUGH S, SCHLEUSNER D, PIETRZIK C, SKUTELLA T, BEHL C: Glycogen synthase kinase 3beta links neuroprotection by 17beta-estradiol to key Alzheimer processes. Neuroscience (2005) 132(3):581-589.
   PubMed Web of Science ®Google Scholar
• KOUZMENKO AP, TAKEYAMA K, ITO S et al.: Wnt/beta-catenin and estrogen signaling converge in vivo. J. Biol. Chem. (2004) 279(39):40255-40258.
   PubMed Web of Science ®Google Scholar
• MEDUNJANIN S, HERMANI A, DE SERVI B et al.: Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor-alpha and is involved in the regulation of receptor activity. J. Biol. Chem. (2006) In Press.
   Google Scholar
• MENDEZ P, GARCIA-SEGURA LM: Phosphatidyl inositol 3 kinase (PI3K) and glycogen synthase kinase 3 (GSK3) regulate estrogen receptor mediated transcription in neuronal cells. Endocrinology (2006) Epub ahead of print.
   Google Scholar
• SHAW PC, DAVIES AF, LAU KF et al.: Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and -3 beta encoding genes. Genome (1998) 41(5):720-727.
   PubMed Web of Science ®Google Scholar
• HANSEN L, ARDEN KC, RASMUSSEN SB et al.: Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3alpha and beta isoforms in patients with NIDDM. Diabetologia (1997) 40(8):940-946.
   PubMed Web of Science ®Google Scholar
• BADENHOP RF, MOSES MJ, SCIMONE A et al.: A genome screen of 13 bipolar affective disorder pedigrees provides evidence for susceptibility loci on chromosome 3 as well as chromosomes 9, 13 and 19. Mol. Psychiatry (2002) 7(8):851-859.
   PubMedGoogle Scholar
• LANDER E, KRUGLYAK L: Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat. Genet. (1995) 11(3):241-247.
   PubMed Web of Science ®Google Scholar
• RUSS C, LOVESTONE S, POWELL JF: Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer’s disease. Mol. Psychiatry (2001) 6(3):320-324.
   PubMed Web of Science ®Google Scholar
• KWOK JB, HALLUPP M, LOY CT et al.: GSK3B polymorphisms alter transcription and splicing in Parkinson’s disease. Ann. Neurol. (2005) 58(6):829-839.
   PubMed Web of Science ®Google Scholar
• TUBAZIO V, BENEDETTI F, SERRETTI A et al.: Glycogen synthase kinase (GSK) gene promoter polymorphism: a TDT and haplotype approach in mood disorders. Am. J. Med. Genet. (2004) 130B(1):37 (P1.24).
   Google Scholar
• NISHIGUCHI N, BREEN G, RUSS C, ST CLAIR D, COLLIER D: Association analysis of the glycogen synthase kinase-3beta gene in bipolar disorder. Neurosci. Lett. (2006) 394(3):243-245.
   PubMedGoogle Scholar
• LEE KY, AHN YM, JOO EJ et al.: No association of two common SNPs at position -1727 A/T, -50 C/T of GSK-3 beta polymorphisms with schizophrenia and bipolar disorder of Korean population. Neurosci. Lett. (2006) 395(2):175-178.
   PubMedGoogle Scholar
• BENEDETTI F, SERRETTI A, PONTIGGIA A et al.: Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci. Lett. (2005) 376(1):51-55.
   PubMed Web of Science ®Google Scholar
• BENEDETTI F, BERNASCONI A, LORENZI C et al.: A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci. Lett. (2004) 355(1-2):37-40.
   PubMed Web of Science ®Google Scholar
• BENEDETTI F, SERRETTI A, COLOMBO C et al.: A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci. Lett. (2004) 368(2):123-126.
   PubMed Web of Science ®Google Scholar
• SZCZEPANKIEWICZ A, SKIBINSKA M, HAUSER J et al.: Association analysis of the GSK-3beta T-50C gene polymorphism with schizophrenia and bipolar disorder. Neuropsychobiology (2006) 53(1):51-56.
   PubMedGoogle Scholar
• EINAT H, MANJI HK, BELMAKER RH: New approaches to modeling bipolar disorder. Psychopharmacol. Bull. (2003) 37(1):47-63.
   PubMedGoogle Scholar
• LAMBERTY Y, MARGINEANU DG, KLITGAARD H: Effect of the new antiepileptic drug levetiracetam in an animal model of mania. Epilepsy Behav. (2001) 2(5):454-459.
   PubMedGoogle Scholar
• MAMELAK M: An amphetamine model of manic depressive illness. Int. Pharmacopsychiatry (1978) 13(4):193-208.
   PubMedGoogle Scholar
• MURPHY DL, BRODIE HK, GOODWIN FK, BUNNEY WE Jr.: Regular induction of hypomania by L-dopa in ‘bipolar’ manic-depressive patients. Nature (1971) 229(5280):135-136.
   PubMed Web of Science ®Google Scholar
• VAN KAMMEN DP, MURPHY DL: Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia (1975) 44(3):215-224.
   PubMedGoogle Scholar
• HUEY LY, JANOWSKY DS, JUDD LL et al.: Effects of lithium carbonate on methylphenidate-induced mood, behavior, and cognitive processes. Psychopharmacology (Berl) (1981) 73(2):161-164.
   PubMed Web of Science ®Google Scholar
• BEAULIEU JM, SOTNIKOVA TD, YAO WD et al.: Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. USA (2004) 101(14):5099-5104.
   PubMed Web of Science ®Google Scholar
• SVENNINGSSON P, TZAVARA ET, CARRUTHERS R et al.: Diverse psychotomimetics act through a common signaling pathway. Science (2003) 302(5649):1412-1415.
   PubMed Web of Science ®Google Scholar
• BHAT RV, XUE Y, BERG S et al.: Structural insights and biological effects of glycogen synthase kinase 3 specific inhibitor AR-A014418. J. Biol. Chem. (2003) 278(46):45937-45945.
   PubMed Web of Science ®Google Scholar
• NOBLE W, PLANEL E, ZEHR C et al.: Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA (2005) 102(19):6990-6995.
   PubMed Web of Science ®Google Scholar
• GOULD TD, EINAT H, BHAT R, MANJI HK: AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. (2004):1-4.
   PubMedGoogle Scholar
• PORSOLT RD, LE PICHON M, JALFRE M: Depression: a new animal model sensitive to antidepressant treatments. Nature (1977) 266(5604):730-732.
   PubMed Web of Science ®Google Scholar
• KAIDANOVICH-BEILIN O, MILMAN A, WEIZMAN A, PICK CG, ELDAR-FINKELMAN H: Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol. Psychiatry (2004) 55(8):781-784.
   PubMedGoogle Scholar
• ILOUZ R, KAIDANOVICH O, GURWITZ D, ELDAR-FINKELMAN H: Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem. Biophys. Res. Commun. (2002) 295(1):102-106.
   PubMed Web of Science ®Google Scholar
• KROCZKA B, BRANSKI P, PALUCHA A, PILC A, NOWAK G: Antidepressant-like properties of zinc in rodent forced swim test. Brain Res. Bull. (2001) 55(2):297-300.
   PubMed Web of Science ®Google Scholar
• NOWAK G, SZEWCZYK B, WIERONSKA JM et al.: Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res. Bull. (2003) 61(2):159-164.
   PubMed Web of Science ®Google Scholar
• KROCZKA B, ZIEBA A, DUDEK D, PILC A, NOWAK G: Zinc exhibits an antidepressant-like effect in the forced swimming test in mice. Pol. J. Pharmacol. (2000) 52(5):403-406.
   PubMedGoogle Scholar
• SZEWCZYK B, BRANSKI P, WIERONSKA JM et al.: Interaction of zinc with antidepressants in the forced swimming test in mice. Pol. J. Pharmacol. (2002) 54(6):681-685.
   PubMedGoogle Scholar
• WYSKA E, SZYMURA-OLEKSIAK J, OPOKA W et al.: Pharmacokinetic interaction after joint administration of zinc and imipramine in forced swim test in mice. Pol. J. Pharmacol. (2004) 56(4):479-484.
   PubMedGoogle Scholar
• NOWAK G, SIWEK M, DUDEK D, ZIEBA A, PILC A: Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol. J. Pharmacol. (2003) 55(6):1143-1147.
   PubMedGoogle Scholar
• FREDERICKSON CJ, KOH JY, BUSH AI: The neurobiology of zinc in health and disease. Nat. Rev. Neurosci. (2005) 6(6):449-462.
   PubMed Web of Science ®Google Scholar
• ELDAR-FINKELMAN H: Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. (2002) 8(3):126-132.
   Google Scholar
• COHEN P, GOEDERT M: GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. (2004) 3(6):479-487.
   PubMed Web of Science ®Google Scholar
• MARTINEZ A, CASTRO A, DORRONSORO I, ALONSO M: Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. (2002) 22(4):373-384.
   PubMed Web of Science ®Google Scholar
• MARTINEZ A, ALONSO M, CASTRO A, PEREZ C, MORENO FJ: First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer’s disease. J. Med. Chem. (2002) 45(6):1292-1299.
   PubMed Web of Science ®Google Scholar
• PLOTKIN B, KAIDANOVICH O, TALIOR I, ELDAR-FINKELMAN H: Insulin mimetic action of synthetic phosphorylated Peptide inhibitors of glycogen synthase kinase-3. J. Pharmacol. Exp. Ther. (2003) 305(3):974-980.
   PubMed Web of Science ®Google Scholar
• KAIDANOVICH-BEILIN O, ELDAR-FINKELMAN H: Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J. Pharmacol. Exp. Ther. (2006) 316(1):17-24.
   PubMed Web of Science ®Google Scholar
• COHEN Y, CHETRIT A, SIROTA P, MODAN B: Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med. Oncol. (1998) 15(1):32-36.
   PubMedGoogle Scholar
• GOULD TD, GRAY NA, MANJI HK: Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacol. Res. (2003) 48(1):49-53.
   PubMedGoogle Scholar
• GOULD TD, MANJI HK: Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 30(7):1223-1237.
   PubMed Web of Science ®Google Scholar
• BUNNEY WE, JR., DAVIS JM: Norepinephrine in depressive reactions. A review. Arch. Gen. Psychiatry (1965) 13(6):483-494.
   PubMed Web of Science ®Google Scholar
• SCHILDKRAUT JJ: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry (1965) 122(5):509-522.
   PubMed Web of Science ®Google Scholar
• CHUANG DM, CHEN R, CHALECKA-FRANASZEK E et al.: Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord. (2002) 4:129-116.
   PubMed Web of Science ®Google Scholar
• MANJI HK, MOORE GJ, CHEN G: Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol. Psychiatry (1999) 46(7):929-940.
   Google Scholar
• JOPE RS, BIJUR GN: Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Mol. Psychiatry (2002) 7(Suppl. 1):S35-S45.
   PubMed Web of Science ®Google Scholar
• SMITH E, FRENKEL B: Glucocorticoids inhibit LEF/TCF transcriptional activity in differentiating osteoblasts in a GSK3β-dependent and independent manner. J. Biol. Chem. (2004) 280(3):2388-2394.
   PubMedGoogle Scholar
• OHNAKA K, TANABE M, KAWATE H, NAWATA H, TAKAYANAGI R: Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem. Biophys. Res. Commun. (2005) 329(1):177-181.
   PubMed Web of Science ®Google Scholar
• KLEMFUSS H: Rhythms and the pharmacology of lithium. Pharmacol. Ther. (1992) 56(1):53-78.
   PubMed Web of Science ®Google Scholar
• WEHR TA, WIRZ-JUSTICE A: Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria (1982) 15(1):31-39.
   PubMedGoogle Scholar
• BUNNEY WE, BUNNEY BG: Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacology (2000) 22(4):335-345.
   PubMed Web of Science ®Google Scholar
• MARTINEK S, INONOG S, MANOUKIAN AS, YOUNG MW: A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell (2001) 105(6):769-779.
   PubMed Web of Science ®Google Scholar
• YIN L, WANG J, KLEIN PS, LAZAR MA: Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science (2006) 311(5763):1002-1005.
   PubMed Web of Science ®Google Scholar
• HARADA Y, SAKAI M, KURABAYASHI N, HIROTA T, FUKADA Y: Ser-557-phosphorylated mCRY2 is degraded upon synergistic phosphorylation by glycogen synthase kinase-3 beta. J. Biol. Chem. (2005) 280(36):31714-31721.
   PubMed Web of Science ®Google Scholar
• PICCHINI AM, MANJI HK, GOULD TD: GSK-3 and neurotrophic signaling: novel targets underlying the pathophysiology of mood disorders? Drug Discov. Today Dis. Mech. (2004) 1(4):419-428.
   Google Scholar